Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Cidofovir

Cidofovir: 1 brand, 2 generics; first approved Jun 26, 1996; generic available.

Generic availableHas discontinued products
Generic status & protection

Generic available: 2 ANDA applications approved.

Brands (NDA)
1
Generics (ANDA)
2
Listed patents
0
Presentations
3

Brand (NDA) products

Originator applications
  • NDA 0206381996
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 375MG BASE/5ML (EQ 75MG BASE/ML)SOLUTIONINTRAVENOUSDiscontinued

Generic (ANDA) products (2)

Abbreviated applications
  • CIDOFOVIR
    ANDA 2025012012
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 375MG BASE/5ML (EQ 75MG BASE/ML)SOLUTIONINTRAVENOUSRxAP
  • CIDOFOVIRRS
    ANDA 2012762012
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 375MG BASE/5ML (EQ 75MG BASE/ML)SOLUTIONINTRAVENOUSRxAP

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Approval history

FDA approval span
First approval
30 yr 7 mo ago
Most recent approval
14 yr 3 mo ago

Approvals span 1996–2012 across 3 FDA applications.

Brand (NDA) 133%
Generic (ANDA) 267%

Cidofovir: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.